Compass Therapeutics (CMPX) Assets Average (2018 - 2026)

Compass Therapeutics (CMPX) has 9 years of Assets Average data on file, last reported at $212.4 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 56.24% year-over-year to $212.4 million; the trailing twelve-month figure through Mar 2026 stood at $212.4 million (up 56.24% YoY), and the FY2025 full-year result was $180.0 million, up 21.1% from the prior year.
• Assets Average fell to $212.4 million in Q1 2026, from $225.4 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $225.4 million in Q4 2025 to a low of $124.1 million in Q2 2025.
• A 5-year average of $164.3 million and a median of $159.0 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average jumped 199.99% in 2022 and dropped 21.66% in 2025, its largest moves.
• Tracing CMPX's Assets Average over 5 years: stood at $163.7 million in 2022, then decreased by 0.17% to $163.5 million in 2023, then retreated by 11.43% to $144.8 million in 2024, then soared by 55.7% to $225.4 million in 2025, then retreated by 5.79% to $212.4 million in 2026.
• Business Quant data shows CMPX's Assets Average at $212.4 million in Q1 2026, $225.4 million in Q4 2025, and $174.0 million in Q3 2025.